View in a different locale / language
Eurofins Genomics offers comprehensive biopharma services designed to support pharmaceutical and biotechnology industries in their research, development, and production efforts. With cutting-edge technology, including Sanger sequencing and Next Generation Sequencing (NGS), we ensure precise, reliable data to meet the growing needs of the biopharma sector.
By utilising Sanger sequencing, we help to ensure the authenticity and integrity of cell lines. Our precise identification methods safeguard against cross-contamination and misidentification, supporting reliable research outcomes.
MID services provide accurate detection of microorganisms critical for research, development, and production. Eurofins Genomics uses advanced genomic techniques to identify microbial species efficiently.
We deliver deep insights into the relationship between an individual's genetic makeup and drug response. We offer:
We provide thorough testing of microbial cell banks, offering:
RNA-Seq analysis plays a key role in assessing drug treatments and identifying gene targets in clinical trials. This service helps streamline drug development by analysing gene expression to understand the effects of drugs at a molecular level.
Ensure genomic stability with our master and working seed stock testing. These services demonstrate the stability of genotypes following passages and include:
NGS is integral to the discovery of new genomic biomarkers, mutation detection, and personalized medicine. Our services include:
We offer adventitious agent identification services, crucial for the safety and effectiveness of biopharmaceuticals: